Diazepam Treatment to Increase the Cerebral GABAergic Activity in Acute Stroke: A Feasibility Study in 104 Patients (original) (raw)
Article navigation
Research Articles| October 27 2000
aDepartment of Neurology and
Search for other works by this author on:
cDepartment of Neurology, Maasland Hospital, Sittard, The Netherlands
Search for other works by this author on:
aDepartment of Neurology and
Search for other works by this author on:
bClinical Research Unit, University Hospital, Maastricht, and
Search for other works by this author on:
Cerebrovasc Dis (2000) 10 (6): 437–440.
Abstract
In preparation of a trial on the neuroprotective effect of GABAergic activation by a benzodiazepine, we performed a feasibility study in 104 patients with acute (less than 24 h) stroke. 5 mg diazepam twice daily for 5 days (n = 44) was well tolerated, feasible, and appeared to be safe. Testing a dose of 10 mg twice daily for 5 days (n = 17) was stopped early because of drowsiness around day 5, interfering with regular patient care. A dose of 10 mg twice daily for 3 days was well tolerated, despite reported drowsiness in 12 of 43 patients. First-dose application by rectiole was feasible in 97% of the 104 patients. No blood pressure drop or respiratory arrest or insufficiency were detected, whereas the 2-week case fatality rate was similar to that of controls matched for age, sex, and stroke severity. We conclude that testing the GABAergic activity during the acute phase of stroke by 10 mg diazepam twice daily for 3 days is well tolerated and practically feasible, and it does not subject patients to an increased risk of potential serious adverse effects. Preparations for a large randomized trial are in a final stage.
References
Tecoma ES, Choi DW: GABAergic neocortical neurons are resistant to NMDA receptor-mediated injury. Neurology 1989;39:676–682.
Hossmann KA: Periinfarct depolarizations. Cerebrovasc Brain Metab Rev 1996;8:195–208.
Kelly PT, McCullock J: The effects of the GABAergic agonist muscimol upon the relationship between local blood flow and glucose utilisation. Brain Res 1983;258:338–342.
Edvinsson L, Krause DN: Pharmacological characterisation of GABA receptors mediating vasodilatation of cerebral arteries in situ. Brain Res 1979;173:89–97.
Madden UP: Effect of γ-aminobutyric acid modulation on neuronal ischemia in rabbits. Stroke 1994;25:271–275.
Lyden PD, Lonzo L: Combination therapy protects ischemic brain in rats: A glutamate antagonist plus a γ-aminobutyric acid antagonist. Stroke 1994;25:184–196.
Snape MF, Baldwin HA, Cross AJ, Green AR: The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischemia in the rat. Neuroscience 1993;53:837–844.
Saji M, Reis D: Delayed transneuronal death of substantia nigra neurons prevented by γ-aminobutyric acid agonist. Science 1987;235:66–67.
Voll CL, Auer RN: Postischemic seizures and necrotizing ischemic brain damage: Neuroprotective effect of postischemic diazepam and insulin. Neurology 1991;41:423–428.
Johansen F, Dierner NH: Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal Ca1 pyramidal cells. Acta Neurol Scand 1991;84:1–6.
Zweifler R, Lyden P: Muscimol improves functional outcome after transient middle cerebral artery occlusion in normo- and hypothermic rats. Stroke 1995;26:115.
Lyden P: GABA and neuroprotection; in Green AR, Cross AJ (eds): Neuroprotective Agents and Cerebral Ischemia. New York, Acadamic Press, 1997;chap 10.
Lyden P, Jackson-Friedmann C, Lonzo-Doktor L: Medical therapy for intracerebral hematoma with the γ-aminobutyric acid-A agonist muscimol. Stroke 1997;28:387–391.
Lodder J, Heuts-van Raak L, Kessels F: GABAergic stimulation by benzodiazepines at stroke onset may ameliorate functional outcome in cardioembolic stroke patients. Cerebrovasc Dis 1996;6:118.
Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PMM, Ashwood T, Claesson L: Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled, trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999;30:21–28.
Otomo E, Araki G, Mori A, Kurihara M: Clinical evaluation of GABA in the treatment of cerebrovascular disorders: Multi-center double-blind study in comparison with pyrithioxine and placebo. Arzneimittelforschung 1981;31:1511–1523.
Akaike N, Inomata N, Tokutomi N: Contribution of chloride shifts to the fade of γ-aminobutyric acid-gated currents in frog dorsal root ganglion cells. J Physiol (Lond) 1987;391:219–234.
Twyman RE, MacDonald RL: Antiepileptic drug regulation of GABAA receptor channels; in Tunnicliff G, Raess BU (eds): GABA Mechanisms in Epilepsy. New York, Wiley-Liss, 1991, chap 4, pp 84–104.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
Lyden PD, Ashwood T, Claesson L, Odergren T, Friday GH, Martin-Munley S: The Clomethiazole Acute Stroke Study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a phase III trial in the United States and Canada. J Stroke Cerebrovasc Dis 1998;7:435–441.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 